Literature DB >> 18266120

Gender-related risk of myocardial involvement in systemic amyloidosis.

Claudio Rapezzi1, Letizia Riva, Cristina C Quarta, Enrica Perugini, Fabrizio Salvi, Simone Longhi, Paolo Ciliberti, Francesca Pastorelli, Elena Biagini, Ornella Leone, Robin M T Cooke, Letizia Bacchi-Reggiani, Alessandra Ferlini, Michele Cavo, Giampaolo Merlini, Stefano Perlini, Sonia Pasquali, Angelo Branzi.   

Abstract

To investigate associations between gender and myocardial involvement in systemic amyloidosis, we reviewed all patients presenting between 1994 and September 2006 in our institutional network (100 AL and 98 familial transthyretin-related amyloidosis (ATTR) patients, plus 12 elderly men with senile systemic amyloidosis). We focused on echocardiographic descriptors of myocardial involvement (height-indexed mean left ventricular (LV) wall thickness, LV mass index), and baseline LV function. Among familial ATTR patients, female prevalence was lower within the highest tertile of either echocardiographic indicator of myocardial involvement. Gender was independently associated with height-indexed mean LV wall thickness (as were gene mutations). Female prevalence appeared rather similar across the different neurological stages. Within the subgroup of familial ATTR patients with amyloidotic cardiomyopathy, women tended to display a considerably less severe morphological and functional echocardiographic profile. We explored the possible role of female sex hormones by considering menopausal status: women in the highest tertile of mean LV wall thickness index were more often postmenopausal than those in the other two tertiles and had a much higher ( approximately 15 years) mean age; analogous age-related associations were not observable for men. In conclusion, these findings raise the hypothesis that some biological characteristic associated with female gender protects against myocardial involvement in familial ATTR.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18266120     DOI: 10.1080/13506120701815373

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  23 in total

Review 1.  Transthyretin-related amyloidoses and the heart: a clinical overview.

Authors:  Claudio Rapezzi; Candida Cristina Quarta; Letizia Riva; Simone Longhi; Ilaria Gallelli; Massimiliano Lorenzini; Paolo Ciliberti; Elena Biagini; Fabrizio Salvi; Angelo Branzi
Journal:  Nat Rev Cardiol       Date:  2010-05-18       Impact factor: 32.419

Review 2.  Pathophysiology and treatment of cardiac amyloidosis.

Authors:  Morie A Gertz; Angela Dispenzieri; Taimur Sher
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

Review 3.  Cardiac amyloidosis: the great pretender.

Authors:  Claudio Rapezzi; Massimiliano Lorenzini; Simone Longhi; Agnese Milandri; Christian Gagliardi; Ilaria Bartolomei; Fabrizio Salvi; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

Review 4.  Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.

Authors:  Adam Castaño; Brian M Drachman; Daniel Judge; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

5.  Amyloid in endomyocardial biopsies.

Authors:  Barbara Kieninger; Magdalena Eriksson; Reinhard Kandolf; Philipp A Schnabel; Stefan Schönland; Arnt V Kristen; Ute Hegenbart; Peter Lohse; Christoph Röcken
Journal:  Virchows Arch       Date:  2010-04-08       Impact factor: 4.064

6.  Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review.

Authors:  Pranav Chandrashekar; Laith Alhuneafat; Meghan Mannello; Lana Al-Rashdan; Morris M Kim; Jason Dungu; Kevin Alexander; Ahmad Masri
Journal:  Circ Genom Precis Med       Date:  2021-08-31

7.  Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis.

Authors:  Michele Boldrini; Francesco Salinaro; Roberta Mussinelli; Ambra Raimondi; Alessio Alogna; Francesco Musca; Giovanni Palladini; Giampaolo Merlini; Stefano Perlini
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-01-20       Impact factor: 1.468

Review 8.  Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy.

Authors:  Violaine Plante-Bordeneuve
Journal:  J Neurol       Date:  2014-06-03       Impact factor: 4.849

Review 9.  Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis.

Authors:  Deepa M Gopal; Frederick L Ruberg; Omar K Siddiqi
Journal:  Curr Heart Fail Rep       Date:  2019-10

10.  Sex Differences in the Phenotype of Transthyretin Cardiac Amyloidosis Due to Val122Ile Mutation: Insights from Noninvasive Pressure-Volume Analysis.

Authors:  Jaya Batra; Hannah Rosenblum; Ersilia M Defilippis; Jan M Griffin; Sunil E Saith; Danilo Gamino; Sergio Teruya; Jeffeny De Los Santos; Stephen Helmke; Daniel Burkhoff; Mathew S Maurer
Journal:  J Card Fail       Date:  2020-08-20       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.